Get started
Author

William H. Shingler

Observed names: Shingler Wh, W H Shingler, W. H. Shingler, W. Shingler, W.H. Shingler, William H Shingler, William Shingler
Observed institutions: Rush University Medical Center, Memorial Hermann, Imperial College Healthcare NHS Trust, University of Washington, Sandwell & West Birmingham Hospitals NHS Trust, Manchester Academic Health Science Centre, Royal Bournemouth Hospital, Royal Berkshire Hospital, Warwick Hospital, University of Manchester, Immunocore (United Kingdom), British Society for Rheumatology, The Christie Hospital, Hôpital Ambroise-Paré, Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Autolus (United Kingdom), Oxford BioMedica (United Kingdom), Wojskowy Instytut Medyczny, Centre for Inflammation Research, University Hospital of Lord’s Transfiguration, Bradford Teaching Hospitals NHS Foundation Trust, Houston Methodist Research Institute, University of Edinburgh
ORCID: 0000-0002-3808-9077
Observed ORCID: 0000-0002-3808-9077
OpenAlex ID: A5029658317
Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
2010 · Robert J. Amato, Robert E. Hawkins, et al. · Clinical Cancer Research · 199
CD14-dependent clearance of apoptotic cells by human macrophages: the role of phosphatidylserine
2003 · A Devitt, S Pierce, et al. · Cell Death and Differentiation · 95
Vaccination of Colorectal Cancer Patients with Modified Vaccinia Ankara Encoding the Tumor Antigen 5T4 (TroVax) Given Alongside Chemotherapy Induces Potent Immune Responses
2007 · Richard Harrop, Noel Drury, et al. · Clinical Cancer Research · 90
PDF
Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses
2007 · Richard Harrop, Noel Drury, et al. · Cancer Immunology Immunotherapy · 85
Vaccination of Renal Cell Cancer Patients With Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Alone or Administered in Combination With Interferon-α (IFN-α)
2009 · Robert J. Amato, William Shingler, et al. · Journal of Immunotherapy · 78
Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma
2009 · Howard L Kaufman, Bret Taback, et al. · Journal of Translational Medicine · 75
PDF
Vaccination of Renal Cell Cancer Patients with Modified Vaccinia Ankara Delivering Tumor Antigen 5T4 (TroVax) Administered with Interleukin 2: A Phase II Trial
2008 · Robert J. Amato, William Shingler, et al. · Clinical Cancer Research · 62
Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma.
2016 · Mark R. Middleton, Neil Matthew Steven, et al. · Journal of Clinical Oncology · 43
Vaccination of Patients With Metastatic Renal Cancer With Modified Vaccinia Ankara Encoding the Tumor Antigen 5T4 (TroVax) Given Alongside Interferon-α
2009 · Robert E. Hawkins, Catriona Macdermott, et al. · Journal of Immunotherapy · 43
Cross-trial Analysis of Immunologic and Clinical Data Resulting From Phase I and II Trials of MVA-5T4 (TroVax) in Colorectal, Renal, and Prostate Cancer Patients
2010 · Richard Harrop, William Shingler, et al. · Journal of Immunotherapy · 36
MVA–5T4-induced immune responses are an early marker of efficacy in renal cancer patients
2011 · Richard Harrop, William H. Shingler, et al. · Cancer Immunology Immunotherapy · 34
Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (TroVax)
2012 · Richard Harrop, Peter Treasure, et al. · Cancer Immunology Immunotherapy · 29
Identification and functional validation of MHC class I epitopes in the tumor-associated antigen 5T4
2008 · W. H. Shingler, P. Chikoti, et al. · International Immunology · 26
Recommendations for procurement of starting materials by apheresis for advanced therapy medicinal products
2022 · Lynn Manson, Jacqueline Barry, et al. · Cytotherapy · 9
PDF
Abstract CT106: A phase I/IIa study of IMCgp100: Partial and complete durable responses with a novel first-in-class immunotherapy for advanced melanoma
2015 · Mark R. Middleton, Pippa Corrie, et al. · Cancer Research · 7
Vaccination of renal cell cancer (RCC) patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax [T]) administered + low dose interleukin-2 (IL-2): A phase II trial
2008 · J. Hernandez-McClain, R. J. Amato, et al. · Journal of Clinical Oncology · 6
Activity of MVA 5T4 alone or in combination with either interleukin-2 (IL-2) or interferon-α (IFN) in patients (Pts) with metastatic renal cell cancer (MRCC)
2007 · A. Cao, J. Hernandez-McClain, et al. · Journal of Clinical Oncology · 6
Risk-Based Qualification of Cellular Starting Material Collection Sites: Tools to Determine Scope of Manufacturer Audits and Reduce Duplicative Efforts
2024 · Peter Holman, Kara Wacker, et al. · Transplantation and Cellular Therapy · 4
Case Reports * 1. A Late Presentation of Loeys-Dietz Syndrome: Beware of TGF Receptor Mutations in Benign Joint Hypermobility
2013 · P. Mehta, S. Holder, et al. · Lara D. Veeken · 4
Vaccination of renal cell cancer patients with TroVax (modified vaccinia Ankara delivering the tumor antigen 5T4) plus IFNα: A phase II trial
2008 · R. Harrop, C. Macdermott, et al. · Journal of Clinical Oncology · 4
A phase I/IIa study of IMCgp100: Partial and complete durable responses with a novel first-in-class immunotherapy for advanced melanoma
2015 · Mark R. Middleton, Pippa Corrie, et al. · Cancer Research · 3
IMCgp100: a novel bispecific biologic for the treatment of malignant melanoma.
2013 · Mark R. Middleton, Jason V. Evans, et al. · Cancer Research · 2
Abstract CT329: A Phase I study of IMCgp100: durable responses with a novel first-in-class immunotherapy for advanced melanoma
2014 · Mark Middleton, Jeff Evans, et al. · Cancer Research · 1
A Phase I study of IMCgp100: durable responses with a novel first-in-class immunotherapy for advanced melanoma
2014 · Mark R. Middleton, Jeff Evans, et al. · Cancer Research · 1
Abstract 1238: IMCgp100: a novel bispecific biologic for the treatment of malignant melanoma.
2013 · Mark Middleton, Jeff Evans, et al. · Cancer Research · 1
Works count: 39
Citation count: 951
H-index: 13
I10-index: 13
Year
Topic
Type